Photo from wikipedia
Acquired haemophilia A (AHA) is a rare and potentially life‐threatening bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII). Treatment entails achieving haemostasis with bypassing agents or factor… Click to show full abstract
Acquired haemophilia A (AHA) is a rare and potentially life‐threatening bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII). Treatment entails achieving haemostasis with bypassing agents or factor replacement, and eradication of the inhibitor with immunosuppressive therapy (IST). Due to the rarity of AHA, there are few prospective data to guide management.
Keywords:
hemophilia retrospective;
treatment acquired;
retrospective review;
emicizumab treatment;
treatment;
acquired hemophilia
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!